Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported its annual performance for the period ending December 30, 2003, with the filing made on December 13, 2004. The company, a biopharmaceutical firm focused on discovering, developing, and commercializing treatments for serious medical conditions, is heavily invested in its pipeline of product candidates, including VEGF Trap for cancer and eye diseases, IL-1 Trap for rheumatoid arthritis, IL-4/13 Trap for asthma, and AXOKINE® for obesity. As of the reporting period, Regeneron had not yet generated any sales or profits from commercialized products, reflecting its early-stage development nature. The company's strategy centers on leveraging its scientific research and technology platforms to build an integrated biopharmaceutical business. Significant collaboration agreements were highlighted, notably with Aventis for the VEGF Trap and a terminated collaboration with Novartis for the IL-1 Trap, alongside an ongoing collaboration with Procter & Gamble. These partnerships involve substantial upfront payments, milestone opportunities, and shared development expenses, indicating the capital-intensive nature of drug development and Regeneron's reliance on strategic alliances.
Key Highlights
- 1Regeneron is a biopharmaceutical company focused on developing treatments for serious medical conditions, with product candidates in various stages of clinical development, including VEGF Trap, IL-1 Trap, IL-4/13 Trap, and AXOKINE®.
- 2The company has not generated any sales or profits from commercialized products, underscoring its development-stage status.
- 3Significant collaboration agreements are in place, including a key partnership with Aventis for the VEGF Trap, which includes upfront payments, potential milestones totaling up to $360 million, and shared development costs.
- 4A collaboration with Novartis for the IL-1 Trap was announced as terminated, impacting future development plans and funding for that specific program.
- 5Research and development expenses were substantial, reaching $136.0 million in 2003, reflecting ongoing investment in its pipeline.
- 6The company reported a net loss of $107.5 million for 2003, consistent with its developmental stage.
- 7Regeneron's financial position showed a healthy cash and marketable securities balance of $366.6 million as of December 31, 2003, providing runway for ongoing operations.